+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease



Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease



New England Journal of Medicine 340(25): 1948-1953



Although patients with chronic obstructive pulmonary disease (COPD) should stop smoking, some do not. In a double-blind, placebo-controlled study, we evaluated the effect of the inhaled glucocorticoid budesonide in patients with mild COPD who continued smoking. After a six-month run-in period, we randomly assigned 1277 subjects (mean age, 52 years; mean forced expiratory volume in one second [FEV1], 77 percent of the predicted value; 73 percent men) to twice-daily treatment with 400 microg of budesonide or placebo, inhaled from a dry-powder inhaler, for three years. Of the 1277 subjects, 912 (71 percent) completed the study. Among these subjects, the median decline in the FEV1 after the use of a bronchodilator over the three-year period was 140 ml in the budesonide group and 180 ml in the placebo group (P=0.05), or 4.3 percent and 5.3 percent of the predicted value, respectively. During the first six months of the study, the FEV1 improved at the rate of 17 ml per year in the budesonide group, as compared with a decline of 81 ml per year in the placebo group (P<0.001). From nine months to the end of treatment, the FEV1 declined at similar rates in the two groups (P=0.39). Ten percent of the subjects in the budesonide group and 4 percent of those in the placebo group had skin bruising (P<0.001). Newly diagnosed hypertension, bone fractures, postcapsular cataracts, myopathy, and diabetes occurred in less than 5 percent of the subjects, and the diagnoses were equally distributed between the groups. In patients with mild COPD who continue smoking, the use of inhaled budesonide is associated with a small one-time improvement in lung function but does not appreciably affect the long-term progressive decline.

(PDF emailed within 0-6 h: $19.90)

Accession: 046573783

Download citation: RISBibTeXText

PMID: 10379018

DOI: 10.1056/nejm199906243402503


Related references

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. New England Journal of Medicine 340(25): 1948-1953, June 24, 1999

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial. Lancet (North American Edition) 353(9167): 1819-1823, May 29, 1999

Triple inhaled therapy in stable chronic obstructive pulmonary disease: the earlier, the better? Evaluation of Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:741-50. Expert Opinion on PharmacoTherapy 11(6): 1039-1042, 2010

UPLIFT Study: the effects of long-term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Evaluation of: Tashkin DP, Celli B, Senn S et al.: a 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med (2008) 359(15):1543-1554. Expert Opinion on PharmacoTherapy 10(4): 719-722, 2009

Long-term outcomes in mild/moderate chronic obstructive pulmonary disease in the European community respiratory health survey. American Journal of Respiratory and Critical Care Medicine 180(10): 956-963, 2009

Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine. Respiratory Medicine 93(10): 715-718, 1999

Long-term treatment with inhaled budesonide did not effect bone mineral density or bone markers in patients with chronic obstructive pulmonary disease. Journal of Bone & Mineral Research 14(SUPPL 1): S386, Sept, 1999

Examining the Effects of Age on Health Outcomes of Chronic Obstructive Pulmonary Disease: Results From the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate Endpoints Cohorts. Journal of the American Medical Directors Association 18(12): 1063-1068, 2018

Should inhaled corticosteroids be used in the long term treatment of chronic obstructive pulmonary disease?. Drugs 61(11): 1535-1544, 2001

Correlation of chronic obstructive pulmonary disease assessment test and clinical chronic obstructive pulmonary disease questionnaire score with BODE index in patients of stable chronic obstructive pulmonary disease. Lung India 35(6): 494-498, 2018

Long-term effect of inhaled budesonide in patients with mild to moderate chronic obstructive lung disease. The Osterbro Study. Ugeskrift for Laeger 162(4): 493-497, 2000

Long-Acting Bronchodilator Treatment Type And Chronic Obstructive Pulmonary Disease-Related Inpatient Admission Among Patients With Chronic Obstructive Pulmonary Disease In A Commercially Insured Population. Chest 136(4): 25S-g1-25S-g2, 2009

Long-term treatment with budesonide/formoterol attenuates circulating CRP levels in chronic obstructive pulmonary disease patients of group D. Plos One 12(8): E0183300, 2017

Long-term use of inhaled corticosteroids and risk of upper respiratory tract infection in chronic obstructive pulmonary disease: a meta-analysis. Inhalation Toxicology 29(5): 219-226, 2017

Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis. Lancet. Respiratory Medicine 4(6): 454-462, 2017